ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.01B
1-Year Est. Return
174.02%
1 Year Est. Return
+174.02%
AUM
$1.01B
AUM Growth
+$394M
(+64%)
Holding
251
Top Buys
| 1 | +$27.5M | |
| 2 | +$21.3M | |
| 3 | +$21.3M | |
| 4 |
ETNB
89bio
ETNB
|
+$18.2M |
| 5 |
Lexeo Therapeutics
LXEO
|
+$9.21M |
Top Sells
| 1 | +$146M | |
| 2 | +$18.6M | |
| 3 | +$11M | |
| 4 |
Mineralys Therapeutics
MLYS
|
+$8.49M |
| 5 |
RAPT Therapeutics
RAPT
|
+$7.1M |
Sector Composition
| 1 | Healthcare | 87.56% |
| 2 | Financials | 1.74% |
| 3 | Consumer Discretionary | 0.24% |
| 4 | Communication Services | 0.1% |
| 5 | Technology | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
1
Abivax
ABVX
$9.34B
| $115M | 10.77% |
1,350,826
-1,720,514
|
|
||
2
Keros Therapeutics
KROS
$523M
| $85.3M | 8.01% |
5,389,264
|
|
||
3
Protagonist Therapeutics
PTGX
$5.35B
| $65.7M | 6.17% |
989,182
+41,113
|
|
||
4
Roivant Sciences
ROIV
$14.1B
| $50.6M | 4.76% |
3,347,501
+1,406,704
|
|
||
5
Alpha Architect 1-3 Month Box ETF
BOXX
$9.02B
| $38.4M | 3.61% |
337,125
|
|
||
6
SPDR S&P 500 ETF Trust
SPY
$697B
| $36.4M | 3.42% |
54,684
+32,000
|
|
||
7
Immunovant
IMVT
$3.99B
| $36.1M | 3.39% |
2,241,753
+1,706,687
|
|
||
|
ETNB
8
DELISTED
89bio
ETNB
| $31.1M | 2.92% |
2,113,153
+1,237,170
|
|
||
9
Zai Lab
ZLAB
$2.2B
| $29.4M | 2.77% |
868,780
+18,343
|
|
||
10
Cytokinetics
CYTK
$8.08B
| $28.5M | 2.68% |
518,921
-63,226
|
|
||
|
SEPN
11
Septerna Inc
SEPN
$1.24B
| $22.1M | 2.08% |
1,176,491
+329,264
|
|
||
12
Prothena Corp
PRTA
$553M
| $14.3M | 1.35% |
1,469,098
-1,905,911
|
|
||
13
BridgeBio Pharma
BBIO
$13.8B
| $14.2M | 1.33% |
273,414
+13,755
|
|
||
14
Arbutus Biopharma
ABUS
$810M
| $13.2M | 1.24% |
2,903,226
+77,453
|
|
||
|
15
RAPT Therapeutics
RAPT
$873M
| $13.1M | 1.23% |
507,771
-275,446
|
|
||
16
CytomX Therapeutics
CTMX
$727M
| $12.9M | 1.21% |
4,045,414
+964,000
|
|
||
17
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$43.6B
| $12.4M | 1.17% |
135,585
|
|
||
18
Amylyx Pharmaceuticals
AMLX
$1.56B
| $11.8M | 1.11% |
866,202
-338,899
|
|
||
|
BIOA
19
BioAge Labs
BIOA
$320M
| $11.1M | 1.04% |
1,880,073
-57,050
|
|
||
20
Monopar Therapeutics
MNPR
$555M
| $10.6M | 1% |
129,999
+29,025
|
|
||
21
Crinetics Pharmaceuticals
CRNX
$4.29B
| $10.3M | 0.97% |
248,368
+195,243
|
|
||
|
22
Lexeo Therapeutics
LXEO
$651M
| $10.2M | 0.96% |
1,531,953
+1,386,844
|
|
||
23
CG Oncology
CGON
$3.49B
| $10M | 0.94% |
248,917
-274,299
|
|
||
24
Taysha Gene Therapies
TSHA
$1.21B
| $9.27M | 0.87% |
2,835,680
-174,190
|
|
||
25
Regeneron Pharmaceuticals
REGN
$78.8B
| $8.83M | 0.83% |
15,700
+12,339
|
|